BC Extra | Jul 23, 2019
Company News

July 22 Company Quick Takes: Vertex submits NDA for triple combo; plus VenatoRX and Biohaven

Vertex submits NDA for cystic fibrosis triple combo  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) submitted an NDA seeking Priority Review for a triple combination of elexacaftor (VX-445), tezacaftor and ivacaftor to treat cystic fibrosis. The company is...
BC Extra | Jun 25, 2019
Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
BC Extra | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to...
BC Week In Review | Aug 10, 2018
Company News

Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash. Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera,...
BC Extra | Aug 9, 2018
Company News

Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash. Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera,...
BC Extra | Jul 16, 2018
Company News

Spero nabs funding for antibiotic

Spero Therapeutics Inc. (NASDAQ:SPRO) said it will receive up to $54.2 million from the Biomedical Advanced Research and Development Authority (BARDA) and Defense Threat Reduction Agency (DTRA) to develop SPR994. From BARDA, the company will...
BC Extra | Jun 19, 2018
Politics & Policy

National Academies recommends defense strategies against biosynthetic weapons

While synthetic biology could be weaponized, similar technology could be used to mitigate those potential threats, concludes a report released Tuesday by the National Academies of Sciences, Engineering, and Medicine (NASEM). In the report, NASEM...
BC Extra | Apr 26, 2018
Politics & Policy

Report: rebates topped $89 billion in 2016

A study by the Altarum Center for Value in Health Care reports that drug manufacturers passed $89 billion in rebates for brand name drugs in 2016 to U.S. health plans and insurers, reducing total retail...
BC Week In Review | Mar 16, 2018
Company News

SEC charges Theranos with fraud

The SEC charged blood-based diagnostic company Theranos Inc. (Palo Alto, Calif.), its founding CEO Elizabeth Holmes and former President Ramesh Balwani with fraudulently raising more than $700 million by exaggerating or making false statements to...
BC Extra | Mar 14, 2018
Company News

SEC charges Theranos with fraud

The SEC charged blood-based diagnostic company Theranos Inc. (Palo Alto, Calif.), its founding CEO Elizabeth Holmes and former President Ramesh Balwani with fraudulently raising more than $700 million by exaggerating or making false statements to...
Items per page:
1 - 10 of 255
BC Extra | Jul 23, 2019
Company News

July 22 Company Quick Takes: Vertex submits NDA for triple combo; plus VenatoRX and Biohaven

Vertex submits NDA for cystic fibrosis triple combo  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) submitted an NDA seeking Priority Review for a triple combination of elexacaftor (VX-445), tezacaftor and ivacaftor to treat cystic fibrosis. The company is...
BC Extra | Jun 25, 2019
Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
BC Extra | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to...
BC Week In Review | Aug 10, 2018
Company News

Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash. Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera,...
BC Extra | Aug 9, 2018
Company News

Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash. Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera,...
BC Extra | Jul 16, 2018
Company News

Spero nabs funding for antibiotic

Spero Therapeutics Inc. (NASDAQ:SPRO) said it will receive up to $54.2 million from the Biomedical Advanced Research and Development Authority (BARDA) and Defense Threat Reduction Agency (DTRA) to develop SPR994. From BARDA, the company will...
BC Extra | Jun 19, 2018
Politics & Policy

National Academies recommends defense strategies against biosynthetic weapons

While synthetic biology could be weaponized, similar technology could be used to mitigate those potential threats, concludes a report released Tuesday by the National Academies of Sciences, Engineering, and Medicine (NASEM). In the report, NASEM...
BC Extra | Apr 26, 2018
Politics & Policy

Report: rebates topped $89 billion in 2016

A study by the Altarum Center for Value in Health Care reports that drug manufacturers passed $89 billion in rebates for brand name drugs in 2016 to U.S. health plans and insurers, reducing total retail...
BC Week In Review | Mar 16, 2018
Company News

SEC charges Theranos with fraud

The SEC charged blood-based diagnostic company Theranos Inc. (Palo Alto, Calif.), its founding CEO Elizabeth Holmes and former President Ramesh Balwani with fraudulently raising more than $700 million by exaggerating or making false statements to...
BC Extra | Mar 14, 2018
Company News

SEC charges Theranos with fraud

The SEC charged blood-based diagnostic company Theranos Inc. (Palo Alto, Calif.), its founding CEO Elizabeth Holmes and former President Ramesh Balwani with fraudulently raising more than $700 million by exaggerating or making false statements to...
Items per page:
1 - 10 of 255